Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10363649 | 0.94 | — | — | |
| SCHEMBL8781919 | 0.82 | — | — | |
| SCHEMBL217840 | 0.82 | DHODH (0.41) | HCAR2TSHRALDH1A1NPSR1DHODH | |
| SCHEMBL12491707 | 0.82 | DHODH (0.41) | HCAR2TSHRALDH1A1NPSR1DHODH | |
| SCHEMBL5415654 | 0.82 | DHODH (0.41) | HCAR2TSHRALDH1A1NPSR1DHODH | |
| SCHEMBL17024327 | 0.82 | DHODH (0.41) | HCAR2TSHRALDH1A1NPSR1DHODH | |
| SCHEMBL12491709 | 0.82 | DHODH (0.41) | HCAR2TSHRALDH1A1NPSR1DHODH | |
| SCHEMBL17024326 | 0.82 | DHODH (0.41) | HCAR2TSHRALDH1A1NPSR1DHODH | |
| SCHEMBL28247062 | 0.82 | DHODH (0.41) | HCAR2TSHRALDH1A1NPSR1DHODH | |
| SCHEMBL29008433 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60008252-A | — | — | None | — | — | JP | disclosed |
| US-12603275-B2 | Electrochemical cells comprising coated cathode active material and silyl ester phosphonate as electrolyte additive | BASF SE (DE) | 2026-04-14 | — | — | US | disclosed |
| CN-111480257-B | Comprising oligosilylphosphines electrolyte composition of acid ester | 巴斯夫欧洲公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-110915052-B | Heterocyclic sulfonyl fluoride additives for electrolyte compositions of lithium batteries | 巴斯夫欧洲公司 | 2024-04-23 | — | — | CN | disclosed |
| US-11936002-B2 | Electrolyte composition comprising oligomeric silyl ester phosphonates | BASF SE (DE) | 2024-03-19 | — | — | US | disclosed |
| EP-4308573-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | Schrödinger, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-109716578-B | Electrochemical cell comprising difunctional silyl phosphonate | 巴斯夫欧洲公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3724943-B1 | ELECTROLYTE COMPOSITION COMPRISING OLIGOMERIC SILYL ESTER PHOSPHONATES | BASF SE (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-110249466-B | Functionalized sulfonyl fluoride additives for electrolyte compositions for lithium ion batteries | 巴斯夫欧洲公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11444326-B2 | Heterocyclic sulfonyl fluoride additives for electrolyte composition for lithium batteries | BASF SE (DE) | 2022-09-13 | — | — | US | disclosed |
| EP-2768064-A1 | Use of substituted alkynyl sulfonates, carbonates and oxalates as additives in electrolytes of secondary lithium-ion batteries | BASF SE (DE) | 2014-08-20 | — | — | EP | disclosed |
| US-20140193707-A1 | SULFUR-CONTAINING ADDITIVES FOR ELECTROCHEMICAL OR OPTOELECTRONIC DEVICES | BASF SE (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2014095407-A1 | USE OF FLUOROISOPROPYL DERIVATIVES AS ADDITIVES IN ELECTROLYTES | BASF SE (DE) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014083113-A1 | CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-06-05 | — | — | WO | disclosed |
| WO-2011021036-A1 | POLYKETIDES ANALOGUES AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LIMITED (GB) | 2011-02-24 | — | — | WO | disclosed |
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | NOGRA PHARMA LIMITED (IE) | 2011-02-17 | — | — | US | disclosed |
| EP-2222287-A2 | MULTITARGET COMPOUNDS ACTIVE AT A PPAR AND CANNABINOID RECEPTOR | Giuliani International Limited (IE) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009080821-A2 | RECEPTOR TARGETING LIGANDS | GIULIANI INTERNATIONAL LIMITED (IE) | 2009-07-02 | — | — | WO | disclosed |
| US-5180418-A | HERBICIDALLY ACTIVE THIADIAZABICYCLONONANES AND NONENES | CIBA-GEIGY CORPORATION (US) | 1993-01-19 | — | — | US | disclosed |
| JP-S608252-A | SALICYLIC ACID DERIVATIVE AND HERBICIDE | SHOWA DENKO KK | 1985-01-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12603275-B2 | Electrochemical cells comprising coated cathode active material and silyl ester phosphonate as electrolyte additive | ILK, ITGB7, ITGAL | HCAR2 4856/4885TSHR 3625/4885ALDH1A1 3369/4885 |
| US-20110039808-A1 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor | PPARA, PPARG, PPARD | HCAR2 9/4885TSHR 586/4885ALDH1A1 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.